Xiamen Amoytop Biotech: Announcement on the approval of the drug clinical trial approval letter for the newly approved indications of Pegintron.
Xiamen Amoytop Biotech: Investor Relations Activity Record (June 18, 2024)
Xiamen Amoytop Biotech: Investor Relations Activity Schedule (May 22, 2024)
Xiamen Amoytop Biotech: Investor Relations Activity Schedule (May 16, 2024)
Xiamen Amoytop Biotech: Announcement on participating in the 3rd “Improving Quality, Efficiency, and Reward” special session of the Science and Technology Innovation Board's 2023 Group Results Briefing
Xiamen Amoytop Biotech: Announcement on participating in the 2023 Annual Report Performance Briefing and Online Investor Reception Day for Listed Companies in the Xiamen Area
Tebao Biotech: Investor Relations Activity Record Form (2023 Biological Products Special Group Performance Briefing)
Tebao Biotech: Guojin Securities Co., Ltd.'s 2023 Continuous Supervision and Follow-up Report on Tebao Biotech
Tebao Biotech: Voluntary Disclosure Notice on Passing High-tech Enterprise Certification
Tebao Biotech: Announcement on participating in the 2023 Biological Products Special Group Performance Briefing
Tebao Biotech: Investor Relations Activity Record Form (April 1, 2024)
Tebao Biotech: Rongcheng Certified Public Accountants (Special General Partnership) Verification Report on the Storage and Actual Use of the Company's 2023 Raised Funds
Tebao Biotech: Related Transaction Management System (Revised in March 2024)
Tebao Biotech: Announcement on renewing the employment of an accounting firm
Tebao Biotech: 2023 Audit Report
Tebao Biotech: 2023 Independent Director Debriefing Report (Jiang Xiaohui)
Tebao Biotech: 2023 Environmental, Social and Corporate Governance (ESG) Report
Tebao Biotech: 2023 Internal Control Audit Report
Tebao Biotech: Special opinion of the board of directors on the self-inspection of the independence of independent directors
Tebao Biotech: 2023 Independent Director Debriefing Report (Liu Qi)
No Data